DB
CAI

Dmitry Balyasny’s Caris Life Sciences CAI Stock Holding History

Dmitry Balyasny’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,660,280
Closed -$44.8M – 3693
2025
Q4 		$44.8M Buy
1,660,280
+1,653,363
+23,903% +$46.6M 0.06% 388
2025
Q3 		$209K Sell
6,917
-43,453
-86% -$1.39M ﹤0.01% 2712
2025
Q2 		$1.35M Buy
+50,370
New +$1.36M ﹤0.01% 1924

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dmitry Balyasny's CAI Position: Q1 2026 in Review

Dmitry Balyasny sold out of Caris Life Sciences (CAI) in Q1 2026, closing a stake of 1,660,280 shares — an estimated $44.8M sold.

Dmitry Balyasny first reported a position in CAI in Q2 2025 and held it in 3 quarters. The position peaked at $44.8M in Q4 2025. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • Dmitry Balyasny reported no remaining Caris Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 1,660,280 Caris Life Sciences shares in Q1 2026, an estimated $44.8M.
  • Dmitry Balyasny first reported a position in Caris Life Sciences in Q2 2025 and held it in 3 quarters.
  • Dmitry Balyasny's Caris Life Sciences position peaked at $44.8M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.